NCT07134738 - Dimolegin® (60 mg) for Patients With Moderate COVID-19: A Non-Interventional Study | Biotech Hunter

Enrollment

184

Participants

Timeline

Start Date

June 7, 2024

Primary Completion Date

January 15, 2025

Study Completion Date

January 15, 2025

Conditions

COVID-19

Interventions

DRUG

Dimolegin

Dimolegin® is administered orally once daily,The recommended dose is 60 mg (six 10 mg tablets) once daily.

Trial Locations (6)

Regional Clinical Hospital No. 3, Chelyabinsk

Republican Clinical Hospital named after Professor A.F. Agafonov, Kazan'

Infectious Diseases Clinical Hospital No. 1, Moscow

Infectious Diseases Hospital No. 2, Sochi

Tomsk Regional Hospital, Tomsk

Regional Infectious Diseases Clinical Hospital, Yaroslavl

All Listed Sponsors

lead

Avexima Diol LLC

INDUSTRY